TITLE

Denosumab superior to zoledronic acid for pain reduction in metastatic breast cancer

AUTHOR(S)
Harris, Jason; Southall, Jennifer
PUB. DATE
October 2010
SOURCE
Hem/Onc Today;10/25/2010, Vol. 11 Issue 20, p16
SOURCE TYPE
Newspaper
DOC. TYPE
Article
ABSTRACT
The article discusses research being done on the effectiveness of denosumab and zoledronic acid for reducing pain in metastatic breast cancer, which references a study by Alison T. Stopeck and colleagues presented at the American Society of Clinical Oncology (ASCO) Breast Cancer Symposium in National Harbor, Maryland on October 1-3, 2010.
ACCESSION #
54422838

 

Related Articles

  • HEALTHBRIEFS.  // Investigate;Jul2010, Vol. 10 Issue 114, p75 

    The article reports on the capacity of an experimental drug called eribulin to prolong the survival period of a woman with breast cancer by around 2.5 months.

  • Survival Has Increased with Better Breast Cancer Drugs.  // Clarendon Enterprise (TX);8/23/2007, Vol. 18 Issue 36, p5 

    The article reports on the availability of drugs for breast cancer treatment.

  • Lapatinib monotherapy effective for refractory inflammatory breast cancer.  // Hem/Onc Today;5/25/2009, Vol. 10 Issue 10, p31 

    The article discusses research on the efficacy of monotherapy with lapatinib as treatment for patients with relapsed or refractory HER2-positive inflammatory breast cancer, conducted by B. Kaufman et al, published in a 2009 issue of the "Lancet Oncology" journal.

  • ICI 182,780 (Fulvestrantâ„¢) – the first oestrogen receptor down-regulator – current clinical data. Robertson, J F R // British Journal of Cancer;11/2/2001 Supplement 2, Vol. 85, p11 

    ICI 182,780 (Fulvestrantâ„¢) is the first in a new class of novel, steroidal, 'pure' antioestrogens - the oestrogen receptor (ER) down-regulators. Its unique mode of action and the absence of partial agonist activity make it a candidate for the treatment of advanced breast cancer in both...

  • Urokinase-type plasminogen activator and its inhibitor PAI-1: Predictors of poor response... Foekens, John A.; Look, Maxime P. // JNCI: Journal of the National Cancer Institute;5/17/95, Vol. 87 Issue 10, p751 

    Assesses whether the expression of urokinase-type plasminogen activator (uPA) and its inhibitor plasminogen activator inhibitor-1 (PAI-1) can predict the effectiveness of tamoxifen therapy in recurrent breast cancer. Derivation of the assay levels of uPA and PAI-1 in cystolic extracts; Response...

  • Prevention trials with tamoxifen may be delayed in US. Scherts, John // BMJ: British Medical Journal (International Edition);5/21/94, Vol. 308 Issue 6940, p1318 

    Reports the delay of the plan to investigate the effectiveness of tamoxifen in preventing breast cancer in the United States. Treatments for breast cancer; Plan of the National Institute of Health to pursue with the study; Problems in conducting the study.

  • Benefits of breast cancer drug are obtained in first five...  // Mayo Clinic Health Letter;Mar1996, Vol. 14 Issue 3, p4 

    Reports that the National Cancer Institute (NCI) advised physicians to limit use of the drug tamoxifen (Nolvadex) for treating breast cancer in its early-stage to five years. No additional benefits from longer usage of the drug.

  • BREAST CANCER: TREATMENT OF ELDERLY PATIENTS AND UNCOMMON CONDITIONS. Dixon, J.M.; Sainsbury, J.R.C.; Rodger, A. // BMJ: British Medical Journal (International Edition);11/12/94, Vol. 309 Issue 6964, p1292 

    Examines the treatment of elderly patients with breast cancer. Use of tamoxifen in patients with estrogen receptor positive tumors; Consideration of breast conservation surgery; Effectiveness of mastectomy and axillary node clearance.

  • Olaparib improved response in BRCA-mutated breast, ovarian cancers.  // Hem/Onc Today;8/10/2010, Vol. 11 Issue 15, p14 

    The article discusses research studies on the efficacy of higher dose of olaparib, an oral poly (adenosine phosphate-ribose) polymerase inhibitor, in women with ovarian and breast cancers who carry BRCA1 and BRCA2 gene mutations.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics